Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back program, with a total of 19,289 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 3,478,010 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting its commitment to optimizing financial operations and maintaining a strong market position.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company’s primary products or services are centered around creating treatments that address unmet medical needs in this niche market.
Average Trading Volume: 788,448
Technical Sentiment Signal: Hold
Current Market Cap: A$1.61B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue